/GILD
GILD Stock - Gilead Sciences, Inc.
Healthcare|Drug Manufacturers - GeneralNASDAQ
$124.29+2.32%
+$2.82 (+2.32%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.2%upside
Target: $138.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GILD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$123.05 – $125.53
TARGET (TP)$138.27
STOP LOSS$114.35
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.33
52W High$128.70
52W Low$88.57
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B |
| Gross Profit | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B |
| Gross Margin | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% |
| Operating Income | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B |
| Net Income | $480.00M | $5.67B | $4.59B | $6.22B | $123.00M |
| Net Margin | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% |
| EPS | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 |
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
21
68%
Hold / Neutral
10
32%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
21 Bullish10 Neutral/Bearish
Price Targets
$97
Average Target
↓ 21.7% Downside
Now
$68
Low
$97
Average
$140
High
Based on 41 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Resumed | Buy | $140 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $140 |
| August 19th 2025 | Daiwa Securities | Upgrade | Outperform | $128 |
| August 8th 2025 | Truist | Upgrade | Buy | $127 |
| July 25th 2025 | Needham | Upgrade | Buy | $133 |
| April 22nd 2025 | Cantor Fitzgerald | Resumed | Overweight | $125 |
| March 4th 2025 | Oppenheimer | Reiterated | Outperform | $132← $115 |
| February 18th 2025 | Deutsche Bank | Upgrade | Buy | $120 |
| February 13th 2025 | DZ Bank | Upgrade | Buy | $108 |
| January 10th 2025 | Morgan Stanley | Upgrade | Overweight | $113← $87 |
| December 10th 2024 | BofA Securities | Resumed | Buy | $109 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $110 |
| November 14th 2024 | Citigroup | Initiation | Buy | $125 |
| November 8th 2024 | Maxim Group | Downgrade | Hold | - |
| October 21st 2024 | Leerink Partners | Upgrade | Outperform | $96← $74 |
Earnings History & Surprises
GILDBeat Rate
78%
Last 18 quarters
Avg Surprise
+8.5%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$2.47
Q4 2025
EPS Surprise History
Q1 24
-2.3%
$1.72vs$1.76
Q2 24
+11.4%
$-1.32vs$-1.49
Q3 24
+24.8%
$2.01vs$1.61
Q4 24
+32.0%
$2.02vs$1.53
Q1 25
+9.2%
$1.90vs$1.74
Q2 25
+1.7%
$1.81vs$1.78
Q3 25
+2.6%
$2.01vs$1.96
Q4 25
+16.0%
$2.47vs$2.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $1.86 | — | — | — |
Q4 2025 | Oct 30, 2025 | $2.13 | $2.47 | +16.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.96 | $2.01 | +2.6% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $1.78 | $1.81 | +1.7% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $1.74 | $1.90 | +9.2% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $1.53 | $2.02 | +32.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $1.61 | $2.01 | +24.8% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-1.49 | $-1.32 | +11.4% | ✓ BEAT |
Q1 2024 | Feb 6, 2024 | $1.76 | $1.72 | -2.3% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $1.91 | $2.29 | +19.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $1.60 | $1.34 | -16.3% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $1.63 | $1.37 | -16.0% | ✗ MISS |
Q1 2023 | Feb 2, 2023 | $1.50 | $1.67 | +11.3% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $1.44 | $1.90 | +31.9% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $1.51 | $1.58 | +4.6% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $1.77 | $2.12 | +19.8% | ✓ BEAT |
Q1 2022 | Feb 1, 2022 | $1.53 | $0.69 | -54.9% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $1.75 | $2.65 | +51.4% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $1.76 | $1.87 | +6.3% | ✓ BEAT |
Latest News
Shars of drug companies are higher after announcing deals with President Trump for lower drug prices.
📈 PositiveBenzinga•Dec 19, 2025, 08:34 PM•Also: , ,
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Gilead Expects Financial Impact To Be Manageable In 2026 And Beyond; Additional Terms Of Agreement With U.S. Government Remain Confidential
➖ NeutralBenzinga•Dec 19, 2025, 07:23 PM
Gilead Sciences Reaches U.S. Government Agreement To Cut Drug Costs, Expand U.S. Manufacturing
📈 PositiveBenzinga•Dec 19, 2025, 07:23 PM
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
MHRA Approves Lenacapavir For The Prevention Of Sexually Transmitted HIV-1 Infection
📈 PositiveBenzinga•Dec 19, 2025, 03:14 PM
'Several top drugmakers to lower US prices for some drugs-sources' - Reuters
📈 PositiveBenzinga•Dec 19, 2025, 12:42 PM•Also: , ,
Gilead's Investigational Single-Tablet Regimen Of Bictegravir And Lenacapavir In HIV Treatment Met Primary Endpoint In Phase 3 ARTISTRY-2 Trial
📈 PositiveBenzinga•Dec 15, 2025, 01:32 PM
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $151
📈 PositiveBenzinga•Dec 12, 2025, 05:10 PM
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug
📉 NegativeSeeking Alpha•Dec 12, 2025, 02:13 PM
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
📉 NegativeBenzinga•Dec 12, 2025, 01:33 PM•Also:
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $150
📈 PositiveBenzinga•Dec 10, 2025, 08:06 PM
Gilead's Kite Announced New Analysis Showing Second-Line Yescarta Provides Consistent Benefit In R/R LBCL Patients, Including Those Ineligible For High-Dose Chemotherapy And ASCT
📈 PositiveBenzinga•Dec 7, 2025, 10:25 PM
Truist Securities Assumes Gilead Sciences at Buy, Lowers Price Target of $140
📈 PositiveBenzinga•Nov 24, 2025, 06:10 PM
Gilead Sciences shares are trading higher after the company announced it delivered its first shipment of Lenacapavir HIV-1 capsid inhibitor to Eswatini and Zambia.
📈 PositiveBenzinga•Nov 18, 2025, 05:38 PM
Gilead Sciences Delivers First Shipments Of Lenacapavir, Twice-yearly Injectable HIV-1 Capsid Inhibitor – For The Prevention Of HIV As Pre-exposure Prophylaxis To Eswatini And Zambia
📈 PositiveBenzinga•Nov 18, 2025, 10:45 AM
Needham Maintains Buy on Gilead Sciences, Raises Price Target to $140
📈 PositiveBenzinga•Nov 13, 2025, 06:11 PM
Gilead Sciences Releases Topline Results From Phase 3 ARTISTRY-1 Trial, Showing That Once-Daily Single-Tablet Regimen Of Bictegravir 75 Mg/Lenacapavir 50 Mg Is Non-Inferior To Multi-Tablet Antiretroviral Regimens In Virologically Suppressed Adults With HIV.
📈 PositiveBenzinga•Nov 13, 2025, 01:43 PM
Scotiabank Initiates Coverage On Gilead Sciences with Sector Outperform Rating, Announces Price Target of $140
📈 PositiveBenzinga•Nov 13, 2025, 12:24 PM
Gilead CFO Says Medicare Reform Is About $900M Headwind For HIV Business, $1.2B Headwind For Business Overall
📉 NegativeBenzinga•Nov 10, 2025, 04:12 PM
Frequently Asked Questions about GILD
What is GILD's current stock price?
Gilead Sciences, Inc. (GILD) is currently trading at $124.29 per share. The stock has moved +2.32% today.
What is the analyst price target for GILD?
The average analyst price target for GILD is $138.27, based on 1 analyst.
What sector is Gilead Sciences, Inc. in?
Gilead Sciences, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is GILD's market cap?
Gilead Sciences, Inc. has a market capitalization of $154.20 billion, making it a large-cap company.
Does GILD pay dividends?
No, Gilead Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
BMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
BSX
Boston Scientific Corporation
$95.61
Mkt Cap: $141.7B
DHR
Danaher Corporation
$224.84
Mkt Cap: $161.1B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
NVO
Novo Nordisk A/S
$48.09
Mkt Cap: $213.8B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
SYK
Stryker Corporation
$355.20
Mkt Cap: $135.8B
Explore stocks similar to GILD for comparison